Global Materials | Industrials | Commodities

Rahul Jain

Equity Bottom-Up

<ul>
<li>5-Year Growth: EBITDA doubled to RMB 72.6 bn; production scaled across copper, gold, and lithium through global M&amp;A and low-cost execution.</li>
<li>Capex Plans: USD 10.4 bn over 5 years across copper, lithium, and gold; includes Zijin Gold International spin-off by late 2025.</li>
<li>Zijin is projected to deliver 19–27% CAGR in EBITDA and net profit through 2026, yet trades at just 6.3x 2025E EV/EBITDA — a notable discount to peers trading at 7–8x</li>
</ul>


5-Year Growth: EBITDA doubled to RMB 72.6 bn; production scaled across copper, gold, and lithium through global M&amp;A and low-cost execution.
Capex Plans: USD 10.4 bn over 5 years across copper, lithium, and gold; includes Zijin Gold International spin-off by late 2025.
Zijin is projected to deliver 19–27% CAGR in EBITDA and net profit through 2026, yet trades at just 6.3x 2025E EV/EBITDA — a notable discount to peers trading at 7–8x


Zijin Mining Group: Undervalued, Diversified, and Scaling Fast

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/allkem-ltd" target="_blank" data-smartkarma-citation="entities:3572:1" rel="noopener">Allkem Ltd (AKE AU)</a> saw its last day of trading on 21 December. There was large volume at the close as one major index provider gave it the boot. </li>
<li>Another delayed their treatment at the last minute, and eliminated a cross-flow.</li>
<li>But there is still a lot of net buy flow tomorrow (3 Jan) and the next day in the US. Perhaps more than I expected. </li>
</ul>



Allkem Ltd (AKE AU) saw its last day of trading on 21 December. There was large volume at the close as one major index provider gave it the boot. 
Another delayed their treatment at the last minute, and eliminated a cross-flow.
But there is still a lot of net buy flow tomorrow (3 Jan) and the next day in the US. Perhaps more than I expected. 


Allkem + Livent = Arcadium : Updated Expected Index Flows

<ul>
<li>The Allkem/Livent "merger of equals" discussed in <a href="https://www.smartkarma.com/insights/allkem-livent-ake-au-lthm-us-merger-of-lithium-equals-has-index-surprises" target="_blank" data-smartkarma-citation="insights:101879" rel="noopener">Allkem/Livent (AKE AU | LTHM US) Merger Of Lithium Equals Has Index Surprises</a> and <a href="https://www.smartkarma.com/insights/allkem-livent-enlarged-charging-unit" target="_blank" data-smartkarma-citation="insights:101914" rel="noopener">Allkem/​Livent: Enlarged Charging Unit</a> is on track.</li>
<li>
<a href="https://announcements.asx.com.au/asxpdf/20230928/pdf/05vdp2j4k6sqn9.pdf" target="_blank" rel="noopener">As of the end of last month</a>, all approvals are received or are expected to be received. The Scheme Booklet is expected next month. Deal is expected to close end-CY2023.</li>
<li>The deal STILL has interesting side issues with index. Even more interesting than Newcrest/Newmont. This is an update with more detail as we probably have 8-10 weeks left.</li>
</ul>


The Allkem/Livent "merger of equals" discussed in Allkem/Livent (AKE AU | LTHM US) Merger Of Lithium Equals Has Index Surprises and Allkem/​Livent: Enlarged Charging Unit is on track.

As of the end of last month, all approvals are received or are expected to be received. The Scheme Booklet is expected next month. Deal is expected to close end-CY2023.
The deal STILL has interesting side issues with index. Even more interesting than Newcrest/Newmont. This is an update with more detail as we probably have 8-10 weeks left.


Allkem/Livent (AKE AU | LTHM US) Merger Update:  MUCH More Than Meets The Eye

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Albemarle Corporation reported a solid start to 2026, with first-quarter net sales reaching $1.4 billion, marking a 33% increase year-over-year.</li><li>Adjusted EBITDA more than doubled to $664 million, driven by higher pricing and volumes across both the Energy Storage and Specialties segments, alongside ongoing cost and productivity improvements.</li><li>Energy Storage pricing rose 51%, with volumes up 14%, while Specialties volumes increased 7%.</li></ul>

Albemarle Corporation reported a solid start to 2026, with first-quarter net sales reaching $1.4 billion, marking a 33% increase year-over-year.Adjusted EBITDA more than doubled to $664 million, driven by higher pricing and volumes across both the Energy Storage and Specialties segments, alongside ongoing cost and productivity improvements.Energy Storage pricing rose 51%, with volumes up 14%, while Specialties volumes increased 7%.

Albemarle’s $1.4 Billion Quarter: Can Lithium Pricing Keep The Momentum Alive?

<ul><li>Albemarle Corporation closed 2025 with results that reflected a combination of volume-driven growth, disciplined cost actions, and continued exposure to a volatile lithium pricing environment.</li><li>Fourth-quarter net sales reached $1.4 billion, supported by double-digit volume growth across segments, particularly in Energy Storage, while adjusted EBITDA increased year over year despite margin pressure from foreign exchange and softer specialty pricing.</li><li>For the full year, net sales of $5.1 billion and adjusted EBITDA of $1.1 billion landed at or above prior outlook considerations, underscoring the company’s ability to execute operational improvements even as market conditions remained uneven.</li></ul>

Albemarle Corporation closed 2025 with results that reflected a combination of volume-driven growth, disciplined cost actions, and continued exposure to a volatile lithium pricing environment.Fourth-quarter net sales reached $1.4 billion, supported by double-digit volume growth across segments, particularly in Energy Storage, while adjusted EBITDA increased year over year despite margin pressure from foreign exchange and softer specialty pricing.For the full year, net sales of $5.1 billion and adjusted EBITDA of $1.1 billion landed at or above prior outlook considerations, underscoring the company’s ability to execute operational improvements even as market conditions remained uneven.

Albemarle Corporation: Why EVs & Grid-Scale Storage Are Reshaping the Lithium Demand Curve!

United States

Albemarle Corporation produces specialty and fine chemicals.  The Company's chemicals are additives to or intermediates for plastics, polymers and elastomers, cleaning products, agricultural compounds, pharmaceuticals, photographic chemicals, drilling compounds, and biocides.  Albemarle produces the majority of its products in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Albemarle Corp (ALB US)

Zijin Mining Group: Undervalued, Diversified, and Scaling Fast

In May 2025, Zijin Mining considered halting operations at its Kyzyl-Tashtyg zinc-lead mine in Russia due to sanctions and banking restrictions,...

Rahul Jain

Allkem + Livent = Arcadium : Updated Expected Index Flows

Flows for Livent-become-Arcadium Lithium over the next 3 days are relatively prodigious. This comes from upweights in US indices not matched by...

Travis Lundy

Allkem/Livent (AKE AU | LTHM US) Merger Update: MUCH More Than Meets The Eye

The Allkem/Livent Shareholder Meetings take place 19 Dec. If agreed, this deal gets done quickly. Then we have index fun. The price of lithium...

Travis Lundy

Albemarle’s $1.4 Billion Quarter: Can Lithium Pricing Keep The Momentum Alive?

Albemarle Corporation reported a solid start to 2026, with first-quarter net sales reaching $1.4 billion, marking a 33% increase...

Baptista Research

Albemarle Corporation: Why EVs & Grid-Scale Storage Are Reshaping the Lithium Demand Curve!

Albemarle Corporation closed 2025 with results that reflected a combination of volume-driven growth, disciplined cost actions, and continued...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)